Galapagos has reached a milestone in its immuno-inflammation alliance with GlaxoSmithKline (GSK) by delivering a fifth pre-clinical drug candidate. Galapagos CEO Onno van de Stolpe said the company has identified five candidate drugs of ...
Tags: immuno inflammation, GSK, clinical drug, drug